Pfizer, Novartis pair up on fatty liver drug trials as rivals near finish line - STAT

Pfizer, Novartis pair up on fatty liver drug trials as rivals near finish line - STAT

Pfizer and Novartis tag team NASH

The two drug makers are joining forces to develop experimental combination therapies for the fatty liver disease. While clinical results are yonder, scientists at both Pfizer and Novartis say that using two or more drugs that have different mechanisms in the liver might be the best bet for patients with this disease. 

The financial terms weren't disclosed in this morning's announcement, but the companies plan one or more trials that combine Novartis’ experimental NASH drug tropifexor with up to three different Pfizer compounds.

Read more.